Literature DB >> 31484713

Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis.

Anand J C Eijlers1, Iris Dekker2, Martijn D Steenwijk2, Kim A Meijer2, Hanneke E Hulst2, Petra J W Pouwels2, Bernard M J Uitdehaag2, Frederik Barkhof2, Hugo Vrenken2, Menno M Schoonheim2, Jeroen J G Geurts2.   

Abstract

OBJECTIVE: To determine which pathologic process could be responsible for the acceleration of cognitive decline during the course of multiple sclerosis (MS), using longitudinal structural MRI, which was related to cognitive decline in relapsing-remitting MS (RRMS) and progressive MS (PMS).
METHODS: A prospective cohort of 230 patients with MS (179 RRMS and 51 PMS) and 59 healthy controls was evaluated twice with 5-year (mean 4.9, SD 0.94) interval during which 22 patients with RRMS converted to PMS. Annual rates of cortical and deep gray matter atrophy as well as lesion volume increase were computed on longitudinal (3T) MRI data and correlated to the annual rate of cognitive decline as measured using an extensive cognitive evaluation at both time points.
RESULTS: The deep gray matter atrophy rate did not differ between PMS and RRMS (-0.82%/year vs -0.71%/year, p = 0.11), while faster cortical atrophy was observed in PMS (-0.87%/year vs -0.48%/year, p < 0.01). Similarly, faster cognitive decline was observed in PMS compared to RRMS (p < 0.01). Annual cognitive decline was related to the rate of annual lesion volume increase in stable RRMS (r = -0.17, p = 0.03) to the rate of annual deep gray matter atrophy in converting RRMS (r = 0.50, p = 0.02) and annual cortical atrophy in PMS (r = 0.35, p = 0.01).
CONCLUSIONS: These results indicate that cortical atrophy and cognitive decline accelerate together during the course of MS. Substrates of cognitive decline shifted from worsening lesional pathology in stable RRMS to deep gray matter atrophy in converting RRMS and to accelerated cortical atrophy in PMS only.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Year:  2019        PMID: 31484713     DOI: 10.1212/WNL.0000000000008198

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis.

Authors:  Paolo Preziosa; Elisabetta Pagani; Alessandro Meani; Olga Marchesi; Lorenzo Conti; Andrea Falini; Maria A Rocca; Massimo Filippi
Journal:  J Neurol       Date:  2022-10-06       Impact factor: 6.682

2.  A more unstable resting-state functional network in cognitively declining multiple sclerosis.

Authors:  Tommy A A Broeders; Linda Douw; Anand J C Eijlers; Iris Dekker; Bernard M J Uitdehaag; Frederik Barkhof; Hanneke E Hulst; Christiaan H Vinkers; Jeroen J G Geurts; Menno M Schoonheim
Journal:  Brain Commun       Date:  2022-04-12

3.  Using amyloid PET imaging to diagnose Alzheimer's disease in patients with multiple sclerosis.

Authors:  Magdalena Kolanko; Zarni Win; Neva Patel; Omar Malik; Christopher Carswell; Anastassia Gontsarova; Richard Nicholas; Richard Perry; Paresh Malhotra
Journal:  J Neurol       Date:  2020-06-18       Impact factor: 4.849

4.  Iron Rims in Patients With Multiple Sclerosis as Neurodegenerative Marker? A 7-Tesla Magnetic Resonance Study.

Authors:  A Dal-Bianco; R Schranzer; G Grabner; M Lanzinger; S Kolbrink; G Pusswald; P Altmann; M Ponleitner; M Weber; B Kornek; K Zebenholzer; C Schmied; T Berger; H Lassmann; S Trattnig; S Hametner; F Leutmezer; P Rommer
Journal:  Front Neurol       Date:  2021-12-21       Impact factor: 4.003

Review 5.  Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.

Authors:  Alan J Thompson; William Carroll; Olga Ciccarelli; Giancarlo Comi; Anne Cross; Alexis Donnelly; Anthony Feinstein; Robert J Fox; Anne Helme; Reinhard Hohlfeld; Robert Hyde; Pamela Kanellis; Douglas Landsman; Catherine Lubetzki; Ruth Ann Marrie; Julia Morahan; Xavier Montalban; Bruno Musch; Sarah Rawlings; Marco Salvetti; Finn Sellebjerg; Caroline Sincock; Kathryn E Smith; Jon Strum; Paola Zaratin; Timothy Coetzee
Journal:  Mult Scler       Date:  2021-12-01       Impact factor: 6.312

Review 6.  A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.

Authors:  Laurent Monassier; Ayikoé Guy Mensah-Nyagan; Nicolas Collongues; Guillaume Becker; Valérie Jolivel; Estelle Ayme-Dietrich; Jérôme de Seze; Fabien Binamé; Christine Patte-Mensah
Journal:  Neurol Ther       Date:  2022-05-24

Review 7.  Recent advances in understanding multiple sclerosis.

Authors:  Peter K Stys; Shigeki Tsutsui
Journal:  F1000Res       Date:  2019-12-13

8.  Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis.

Authors:  Marijn Huiskamp; Anand J C Eijlers; Tommy A A Broeders; Jasmin Pasteuning; Iris Dekker; Bernard M J Uitdehaag; Frederik Barkhof; Alle-Meije Wink; Jeroen J G Geurts; Hanneke E Hulst; Menno M Schoonheim
Journal:  Neurology       Date:  2021-06-07       Impact factor: 9.910

Review 9.  Measuring Treatment Response in Progressive Multiple Sclerosis-Considerations for Adapting to an Era of Multiple Treatment Options.

Authors:  Nik Krajnc; Thomas Berger; Gabriel Bsteh
Journal:  Biomolecules       Date:  2021-09-10

10.  Cognitive trajectories in multiple sclerosis: a long-term follow-up study.

Authors:  Antonio Carotenuto; Teresa Costabile; Giuseppe Pontillo; Moccia Moccia; Fabrizia Falco; Maria Petracca; Martina Petruzzo; Cinzia Valeria Russo; Martina Di Stasi; Chiara Paolella; Teresa Perillo; Elena Augusta Vola; Maria Brunella Cipullo; Sirio Cocozza; Roberta Lanzillo; Vincenzo Brescia Morra; Francesco Saccà
Journal:  Neurol Sci       Date:  2021-06-08       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.